Deregulated epigenetic mechanisms are likely involved in the pathogenesis of
myelodysplastic syndromes (MDSs). Which genes are silenced by aberrant promotor …

Aberrant promoter methylation may contribute to the hematopoietic disturbances in
myelodysplastic syndromes (MDS). To explore a possible mechanism, we therefore …

Myelodysplastic syndrome (MDS) is a disorder of hematopoietic stem cells (HSCs) that is
often treated with DNA methyltransferase 1 (DNMT1) inhibitors (5-azacytidine [AZA], 5-aza …

Recurrent mutations implicate several epigenetic regulators in the early molecular
pathobiology of myelodysplastic syndromes (MDS). We hypothesized that MDS subtypes …

Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently
represent an intermediate disease stage before progression to acute myeloid leukemia …

The potential mechanism of myelodysplastic syndromes (MDS) progressing to acute
myeloid leukemia (AML) remains poorly elucidated. It has been proved that epigenetic …

Gene expression profiling signatures may be used to classify the subtypes of
Myelodysplastic syndrome (MDS) patients. However, there are few reports on the global …

Myelodysplastic syndromes (MDS) are clonal diseases of the elderly characterized by
chronic cytopenias, dysplasia and a variable risk of progression to acute myeloid leukemia …

The study of myelodysplastic syndromes (MDS) in murine models has now indicated the
possible involvement of the bone marrow microenvironment in the generation of dysplastic …

Background Myelodysplastic syndrome (MDS) is a preleukemic condition that transforms
into acute myeloid leukemia. However, the genetic events underlying this transformation …